5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): forging a new alliance

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of SCCHN namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum sensitive recurrent or metastatic disease in the first line setting.

          Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.

          Related collections

          Author and article information

          Journal
          101132535
          30097
          Mol Cancer Ther
          Mol. Cancer Ther.
          Molecular cancer therapeutics
          1535-7163
          1538-8514
          13 September 2019
          November 2019
          01 May 2020
          : 18
          : 11
          : 1909-1915
          Affiliations
          [A- ]Department of Hematology and Medical oncology, Winship Cancer Institute, Emory University, Atlanta, GA
          [B- ]Atlantic health System, Morristown NJ, USA
          [C- ]Medical Oncology Department, University of Brescia, Italy
          [D- ]University of Udine School of Medicine, Udine, Italy
          [E- ]Hospital Universitario Central de Asturias, Oviedo, Spain
          [F- ]Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland
          [G- ]Radboud University Medical Center, Nijmegen, The Netherlands
          [H- ]Institute of Oncology, Ljubljana, Slovenia
          [I- ]Antwerp University Hospital, Edegem, Belgium
          [J- ]Coordinator of the International Head and Neck Scientific Group, Padua, Italy
          Author notes
          Corresponding Author: Nabil F Saba, 1365 Clifton Road NE, Building C, Atlanta, GA, 30322, 404 778 1900, nfsaba@ 123456emory.edu
          Article
          PMC6830522 PMC6830522 6830522 nihpa1539716
          10.1158/1535-7163.MCT-19-0214
          6830522
          31676542
          ea22b0e2-f596-4203-bda3-12359c295eee
          History
          Categories
          Article

          Immunotherapy and EGFR in head and neck cancer,EGFR monoclonal antibodies and immunotherapy,combination of anti-EGFR and immunotherapy in head and neck cancer Immunotherapy,EGFR and immunotherapy in SCCHN,combination cetuximab and immunotherapy

          Comments

          Comment on this article